1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Clinical Trial Supply and Logistics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Clinical Trial Supply and Logistics Market, by Service
8.1.1. Logistics & Distribution
8.1.1.1. Market Revenue and Forecast
8.1.2. Storage & Retention
8.1.2.1. Market Revenue and Forecast
8.1.3. Packaging, Labeling, and Blinding
8.1.3.1. Market Revenue and Forecast
8.1.4. Manufacturing
8.1.4.1. Market Revenue and Forecast
8.1.5. Comparator Sourcing
8.1.5.1. Market Revenue and Forecast
8.1.6. Others
8.1.6.1. Market Revenue and Forecast
9.1. Clinical Trial Supply and Logistics Market, by Phase
9.1.1. Phase I
9.1.1.1. Market Revenue and Forecast
9.1.2. Phase II
9.1.2.1. Market Revenue and Forecast
9.1.3. Phase III
9.1.3.1. Market Revenue and Forecast
9.1.4. Phase IV
9.1.4.1. Market Revenue and Forecast
10.1. Clinical Trial Supply and Logistics Market, by End-user
10.1.1. Pharmaceuticals
10.1.1.1. Market Revenue and Forecast
10.1.2. Biologicals
10.1.2.1. Market Revenue and Forecast
10.1.3. Medical Device
10.1.3.1. Market Revenue and Forecast
11.1. Clinical Trial Supply and Logistics Market, by Therapeutic Area
11.1.1. Oncology
11.1.1.1. Market Revenue and Forecast
11.1.2. Cardiovascular Diseases
11.1.2.1. Market Revenue and Forecast
11.1.3. Respiratory Diseases
11.1.3.1. Market Revenue and Forecast
11.1.4. CNS and Mental Disorders
11.1.4.1. Market Revenue and Forecast
11.1.5. Others
11.1.5.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Service
12.1.2. Market Revenue and Forecast, by Phase
12.1.3. Market Revenue and Forecast, by End-user
12.1.4. Market Revenue and Forecast, by Therapeutic Area
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Service
12.1.5.2. Market Revenue and Forecast, by Phase
12.1.5.3. Market Revenue and Forecast, by End-user
12.1.5.4. Market Revenue and Forecast, by Therapeutic Area
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Service
12.1.6.2. Market Revenue and Forecast, by Phase
12.1.6.3. Market Revenue and Forecast, by End-user
12.1.6.4. Market Revenue and Forecast, by Therapeutic Area
12.2. Europe
12.2.1. Market Revenue and Forecast, by Service
12.2.2. Market Revenue and Forecast, by Phase
12.2.3. Market Revenue and Forecast, by End-user
12.2.4. Market Revenue and Forecast, by Therapeutic Area
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Service
12.2.5.2. Market Revenue and Forecast, by Phase
12.2.5.3. Market Revenue and Forecast, by End-user
12.2.5.4. Market Revenue and Forecast, by Therapeutic Area
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Service
12.2.6.2. Market Revenue and Forecast, by Phase
12.2.6.3. Market Revenue and Forecast, by End-user
12.2.6.4. Market Revenue and Forecast, by Therapeutic Area
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Service
12.2.7.2. Market Revenue and Forecast, by Phase
12.2.7.3. Market Revenue and Forecast, by End-user
12.2.7.4. Market Revenue and Forecast, by Therapeutic Area
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Service
12.2.8.2. Market Revenue and Forecast, by Phase
12.2.8.3. Market Revenue and Forecast, by End-user
12.2.8.4. Market Revenue and Forecast, by Therapeutic Area
12.3. APAC
12.3.1. Market Revenue and Forecast, by Service
12.3.2. Market Revenue and Forecast, by Phase
12.3.3. Market Revenue and Forecast, by End-user
12.3.4. Market Revenue and Forecast, by Therapeutic Area
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Service
12.3.5.2. Market Revenue and Forecast, by Phase
12.3.5.3. Market Revenue and Forecast, by End-user
12.3.5.4. Market Revenue and Forecast, by Therapeutic Area
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Service
12.3.6.2. Market Revenue and Forecast, by Phase
12.3.6.3. Market Revenue and Forecast, by End-user
12.3.6.4. Market Revenue and Forecast, by Therapeutic Area
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Service
12.3.7.2. Market Revenue and Forecast, by Phase
12.3.7.3. Market Revenue and Forecast, by End-user
12.3.7.4. Market Revenue and Forecast, by Therapeutic Area
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Service
12.3.8.2. Market Revenue and Forecast, by Phase
12.3.8.3. Market Revenue and Forecast, by End-user
12.3.8.4. Market Revenue and Forecast, by Therapeutic Area
12.4. MEA
12.4.1. Market Revenue and Forecast, by Service
12.4.2. Market Revenue and Forecast, by Phase
12.4.3. Market Revenue and Forecast, by End-user
12.4.4. Market Revenue and Forecast, by Therapeutic Area
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Service
12.4.5.2. Market Revenue and Forecast, by Phase
12.4.5.3. Market Revenue and Forecast, by End-user
12.4.5.4. Market Revenue and Forecast, by Therapeutic Area
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Service
12.4.6.2. Market Revenue and Forecast, by Phase
12.4.6.3. Market Revenue and Forecast, by End-user
12.4.6.4. Market Revenue and Forecast, by Therapeutic Area
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Service
12.4.7.2. Market Revenue and Forecast, by Phase
12.4.7.3. Market Revenue and Forecast, by End-user
12.4.7.4. Market Revenue and Forecast, by Therapeutic Area
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Service
12.4.8.2. Market Revenue and Forecast, by Phase
12.4.8.3. Market Revenue and Forecast, by End-user
12.4.8.4. Market Revenue and Forecast, by Therapeutic Area
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Service
12.5.2. Market Revenue and Forecast, by Phase
12.5.3. Market Revenue and Forecast, by End-user
12.5.4. Market Revenue and Forecast, by Therapeutic Area
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Service
12.5.5.2. Market Revenue and Forecast, by Phase
12.5.5.3. Market Revenue and Forecast, by End-user
12.5.5.4. Market Revenue and Forecast, by Therapeutic Area
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Service
12.5.6.2. Market Revenue and Forecast, by Phase
12.5.6.3. Market Revenue and Forecast, by End-user
12.5.6.4. Market Revenue and Forecast, by Therapeutic Area
13.1. Almac Group
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. DHL
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Parexel
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Thermo Fisher Scientific (Patheon)
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Marken
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Piramal Pharma Solutions
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. UDG Healthcare
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Catalent, Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. FedEx
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Movianto
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
